AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39088062
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pre-hospital heparin)
Trial: 39088076
Drug: Prolonged awake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged awake prone positioning (target > 12 h daily for 7 days)
Trial: 39088212
Drug: ω-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA)
Trial: 39088212
Drug: ω-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA) among APOE*E4 carriers
Trial: 39088370
Drug: Binaural beats
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binaural beats intervention, details on dosage and duration not available
Trial: 39088398
Drug: Apalutamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide plus androgen deprivation therapy (ADT); 240 mg daily for 12 cycles (28-day cycles)
Trial: 39088398
Drug: Apalutamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide plus ADT; 12 months after treatment completion
Trial: 39088510
Drug: Higher number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher number of daily steps
Trial: 39088766
Drug: Nurse-led two-session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led two-session intervention (focused on breathing techniques, postural positions, and fan therapy)
Trial: 39088774
Drug: Standard-dose FFX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose FFX
Trial: 39089004
Drug: Befotertinib 50
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib 50 mg once daily (cohort A)
Trial: 39089004
Drug: Befotertinib 75-100
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib 75-100 mg once daily (cohort B)
Trial: 39089004
Drug: Befotertinib 50
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib 50 mg once daily (cohort A) with brain metastasis
Trial: 39089004
Drug: Befotertinib 50
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib 50 mg once daily (cohort A) without brain metastasis
Trial: 39089004
Drug: Befotertinib 75-100
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib 75-100 mg once daily (cohort B) with brain metastasis
Trial: 39089004
Drug: Befotertinib 75-100
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib 75-100 mg once daily (cohort B) without brain metastasis
Trial: 39089305
Drug: Tepotinib plus
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tepotinib plus osimertinib (oral tepotinib 500 mg plus oral osimertinib 80 mg once daily)
Trial: 39089652
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation containing Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175 over 60 days
Trial: 39089718
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to protein signature with top-down treatment algorithm (anti-tumour necrosis factor agent with/without an immunomodulator)
Trial: 39089718
Drug: Clinical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical management based on stepwise escalation of treatment after failure of first-line treatment
Trial: 39090192
Drug: ADE-RS5 (5-gene-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADE-RS5 (5-gene-drug resistance score)
Trial: 39090323
Drug: N-L-NMMA at
RxNorm normalized name: N-ACETYL L-TYROSINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-L-NMMA at 250 μg/kg per minute combined with trimethaphan at 4 mg/min
Trial: 39090589
Drug: Reported malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reported malaria treatment
Trial: 39090589
Drug: Reported malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reported malaria treatment among febrile individuals
Trial: 39091670
Drug: Deoxycytidine/deoxythymidine (dC/dT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deoxycytidine/deoxythymidine (dC/dT) combination therapy
Trial: 39091669
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (Allisartan starting at 80 mg/day, increased to 160 mg/day at month 2, combined with amlodipine 2.5 mg/day at month 4 if BP remained uncontrolled)
Trial: 39091673
Drug: 2-dose mRNA-1273
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose mRNA-1273 100 μg
Trial: 39091673
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of mRNA-1273 50 μg
Trial: 39093262
Drug: Inclisiran 300
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 300 mg sodium (284 mg inclisiran)
Trial: 39093380
Drug: NSPIT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSPIT plus 500 mg of oral systemic metronidazole three times a day for 7 days
Trial: 39093661
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg at weeks 0 and 4, then every 12 weeks through week 52
Trial: 39093662
Drug: Nutrafol Women's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrafol Women's Vegan Capsules, Nutraceutical Wellness, Inc.
Trial: 39094432
Drug: CER-0001 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-0001 (up to 30 g twice a day)
Trial: 39094560
Drug: NACRT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACRT and PD-1 antibody sintilimab
Trial: 39094743
Drug: PegIFN-α-2a treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN-α-2a treatment for 48 weeks
Trial: 39095571
Drug: Behavioral Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Health (BH) care management including cognitive behavioral therapy, medication adjustments, and case management
Trial: 39095597
Drug: L. major-infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. major-infected Phlebotomus duboscqi
Trial: 39095759
Drug: Digital subtraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital subtraction angiography-guided pancreatic arterial infusion (PAI) of GEMOX chemotherapy
Trial: 39095759
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (IVC) of GEMOX
Trial: 39095866
Drug: Caplacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caplacizumab (10 mg daily) with therapeutic plasma exchange (TPE) and immunosuppression for 30 days post-TPE
Trial: 39095866
Drug: Rituximab administered
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab administered to patients with inhibitor boosting (88.9%) after TPE completion
Trial: 39095866
Drug: Rituximab administered
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab administered to patients without inhibitor boosting prior to TPE completion
Trial: 39095919
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1500 mg)
Trial: 39096659
Drug: ISIS721744 (antisense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS721744 (antisense therapy to block prekallikrein), one subcutaneous dose
Trial: 39096924
Drug: Molecularly guided
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly guided therapy (MGT)
Trial: 39096929
Drug: iscalimab 150
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iscalimab 150 mg
Trial: 39096929
Drug: iscalimab 300
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iscalimab 300 mg
Trial: 39096929
Drug: iscalimab 600
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iscalimab 600 mg
Trial: 39097000
Drug: Happy Mother-Healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Happy Mother-Healthy Baby (HMHB) program based on cognitive behavioral therapy
Trial: 39097315
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (annual oral health awareness visit)
Trial: 39097500
Drug: Nivolumab ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab ± ipilimumab second-line immunotherapy
Trial: 39097566
Drug: Personalized insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalized insulin dosing using reinforcement learning for high-fat meals
Trial: 39097566
Drug: Personalized insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalized insulin dosing using reinforcement learning for meals followed by aerobic exercises
Trial: 39097916
Drug: chemotherapy (nCT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (nCT)
Trial: 39097924
Drug: Tetracycline 500 mg
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline 500 mg three times daily (TET-T)
Trial: 39097924
Drug: Tetracycline 500 mg
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline 500 mg four times daily (TET-F)
Trial: 39098048
Drug: Dehydrated human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydrated human amniotic/chorionic membrane (dHACM) treatment following excisional debridement
Trial: 39098321
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fosravuconazole
Trial: 39098321
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg fosravuconazole
Trial: 39098321
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of fosravuconazole
Trial: 39098325
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus ≤6 monthly incentives (22,500 Tanzanian Shillings, about US$10 each), conditional on visit attendance.
Trial: 39098432
Drug: Preoperative single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative single-dose partial breast irradiation (PBI) followed by breast-conserving surgery (BCS)
Trial: 39098454
Drug: High pre-treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pre-treatment levels of IL-6 (quartile 4 versus 1)
Trial: 39098454
Drug: Pre-treatment inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment inflammatory markers
Trial: 39098658
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment in HR patients
Trial: 39098658
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment in VHR patients
Trial: 39099085
Drug: FLU-aQIV and
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLU-aQIV and RSVPreF3 OA co-administration (Co-Ad)
Trial: 39099085
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of FLU-aQIV and RSVPreF3 OA (Control)
Trial: 39100571
Drug: Vortioxetine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (10-20 mg/day) for 8 weeks
Trial: 39101472
Drug: Inclisiran as
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran as adjunct to high-intensity statin therapy with or without ezetimibe
Trial: 39101472
Drug: Ezetimibe as
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe as adjunct to high-intensity statin therapy
Trial: 39101472
Drug: Evolocumab as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab as adjunct to high-intensity statin therapy and ezetimibe
Trial: 39101472
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as adjunct to high-intensity statin therapy with or without ezetimibe
Trial: 39101607
Drug: SPT (Surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPT (Surgery with Postoperative Physical Therapy)
Trial: 39101607
Drug: PTA (Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTA (Physical Therapy Alone)
Trial: 39101654
Drug: Neoadjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunotherapy (NAIT)
Trial: 39101738
Drug: Knee arthroscopy
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee arthroscopy in addition to exercise therapy (n=150)
Trial: 39101738
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy alone (n=150)
Trial: 39102049
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 2400 mg/day
Trial: 39102111
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein and low glycemic load diet (1.3-1.4 g/kg/day)
Trial: 39102249
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment (physiotherapy plus cognitive behavioral therapy)
Trial: 39102622
Drug: MDT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT plus systemic therapy
Trial: 39102622
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (control)
Trial: 39102624
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year
Trial: 39102712
Drug: Mind-body medicine
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body medicine stress management and lifestyle modification (MBM) program, duration 9 months, guided intervention group (IG)
Trial: 39102712
Drug: Mind-body medicine
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body medicine program (both guided and self-directed)
Trial: 39102756
Drug: Camrelizumab, apatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab, apatinib, and capecitabine combination therapy
Trial: 39102832
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg plus chemotherapy (carboplatin and paclitaxel)
Trial: 39103234
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of monofocal and EDOF IOL implantation
Trial: 39103546
Drug: CC (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (control cracker with conventional flour)
Trial: 39103661
Drug: Nebulised modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised modified cyanoacrylate (1 mL) for anastomotic reinforcement
Trial: 39103923
Drug: Individualized exercise-intensity
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized exercise-intensity prescription targeting pleasure
Trial: 39103947
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rTMS and EEG-guided neurofeedback
Trial: 39105058
Drug: apitegromab 20
RxNorm normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apitegromab 20 mg/kg by intravenous infusion every 4 weeks
Trial: 39105067
Drug: Ravulizumab (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravulizumab (intravenous every 4-8 weeks, dosage depending on body weight)
Trial: 39105794
Drug: tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tislelizumab plus low-dose bevacizumab (Bev)
Trial: 39105849
Drug: Eribulin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin and nivolumab combination
Trial: 39106067
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg orally daily for 54 weeks)
Trial: 39106081
Drug: oleclumab 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oleclumab 3,000 mg (cohort B)
Trial: 39107131
Drug: nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nivolumab monotherapy
Trial: 39107157
Drug: Cabozantinib (2L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (2L therapy)
Trial: 39107157
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies (2L therapy)
Trial: 39107270
Drug: CoronaVac® (3-μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac® (3-μg injections, two doses, 28 days apart)
Trial: 39107706
Drug: TabCAT-BHA intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TabCAT-BHA intervention (tablet-based brain health assessment) with practice supports including education, digital tools, and registered nurse support.
Trial: 39107737
Drug: Roxolid implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxolid implants
Trial: 39107820
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and Treatment of Anxiety and Depression (STAND)
Trial: 39107820
Drug: Original online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original online therapy intervention
Trial: 39108325
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) at 600 mg twice daily
Trial: 39108617
Drug: sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sacituzumab govitecan (10 mg/kg)
Trial: 39109221
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg ivermectin
Trial: 39109241
Drug: Pain Relief
RxNorm normalized name: Pain Relief
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Relief Patch (PRP) delivering blue light for 30 minutes during five treatment sessions
Trial: 39110045
Drug: Crano-cure (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crano-cure (500 mg capsules, two times a day for 28 days)
Trial: 39110045
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg tablets, two times a day for 28 days)
Trial: 39110427
Drug: Low-dose DOAC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DOAC (apixaban, 2.5 mg every 12 hours)
Trial: 39110427
Drug: DAPT (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (aspirin 100 mg per day plus clopidogrel 75 mg per day)
Trial: 39110497
Drug: VR-based training
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR-based training with machine guidance (MG)
Trial: 39110497
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between training duration and VR exam scores for MG group
Trial: 39110531
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg once daily (QD)
Trial: 39110531
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg 3 times/week (TIW)
Trial: 39110531
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg per week (QW)
Trial: 39110721
Drug: Fixation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixation of B2 PFFs around cemented polished taper-slip stems with an intact bone-cement interface
Trial: 39111387
Drug: Eat Well
RxNorm normalized name: MENTHOL 160 mg in 1 mL TOPICAL SPRAY [Cool n Heat Well at Walgreens]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eat Well (intervention arm) - debit card with $80 added monthly for 12 months for fresh, frozen, or canned fruits and vegetables.